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Abstract: Time resolved data of DNA damage and repair after radiotherapy elucidates the relation
between damage, repair, and cell survival. While well characterized in vitro, little is known about
the time-course of DNA damage response in tumors sampled from individual patients. Kinetics
of DNA damage after radiotherapy was assessed in eight dogs using repeated in vivo samples
of tumor and co-irradiated normal tissue analyzed with comet assay and phosphorylated H2AX
(γH2AX) immunohistochemistry. In vivo results were then compared (in silico) with a dynamic
mathematical model for DNA damage formation and repair. Maximum %DNA in tail was observed
at 15–60 min after irradiation, with a rapid decrease. Time-courses of γH2AX-foci paralleled these
findings with a small time delay and were not influenced by covariates. The evolutionary parameter
search based on %DNA in tail revealed a good fit of the DNA repair model to in vivo data for pooled
sarcoma time-courses, but fits for individual sarcoma time-courses suffer from the heterogeneous
nature of the in vivo data. It was possible to follow dynamics of comet tail intensity and γH2AX-foci
during a course of radiation using a minimally invasive approach. DNA repair can be quantitatively
investigated as time-courses of individual patients by integrating this resulting data into a dynamic
mathematical model.
Keywords: DNA damage repair; kinetics; γH2AX-foci; comet assay; dog; radiation; DNA
repair model
1. Introduction
Monitoring the formation of damage in a cell after radiotherapy (RT) and the evaluation of
DNA repair markers may be a means to provide information on intrinsic radiosensitivity and
radio-responsiveness [1–3]. Ionizing radiation used as a cancer treatment relies on the formation
of direct DNA damage or on creating sufficient cellular damage leading to double strand breaks
(DSBs), which in turn trigger the activation of cellular death pathways. Upon damage, the cells
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activate a DNA-damage response, consisting of various pathways which will sense the extent of
damage and induce an effector pathway either leading to cell death, cell cycle arrest, or DNA damage
repair [4]. DNA damage detection from patient samples has been performed for various tumor groups
irradiated ex vivo, resulting in robust correlations with radio-responsiveness, as known from clinical
behavior [2,5]. Furthermore, monitoring the responses towards damage formation and repair from
individual tumors may offer a legitimate chance to monitor cancer treatment and even a possibility
to predict clinical response to treatment [6,7]. This is thought to hold true even in spite of the high
inter-tumoral and inter-patient heterogeneity that is to be expected from patient samples [6,7].
While the time-courses in responses to different DNA damaging agents have been well
characterized in cultured tumor cells in vitro, little is known about the time-course of DNA damage
response in tumor and normal tissues sampled from individual tumor patients [2,5,6,8–10]. Specifically,
actual time-courses from patients undergoing radiation therapy are lacking. Time resolved data of DNA
damage formation and repair can be used to elucidate the relation between DNA damage formation,
repair, and cell survival. It can be expected that, for example, a higher amount of DNA fragments
in the tail of a comet assay or residual phosphorylated H2AX foci (γH2AX-foci) are an indication of
higher initial radiosensitivity.
The aim of this study was twofold: first, we wanted to use the minimally invasive sampling
techniques (fine needle aspirates (FNAs)) and small biopsies for repeated in vivo patient sampling and
subsequent biostatistical quantification of the amounts and time-courses of DNA damage produced by
therapeutic ionizing radiation. As a model, sampling was performed in canine tumor tissue as well
as co-irradiated normal tissue from patients undergoing treatment. In order to study DNA damage
in samples of low cellularity, the comet assay [11–13] was used to detect DNA breaks at the level of
individual cells in a rapid, sensitive, and simple manner. To validate our data from the alkaline comet
assay and to gain additional information, staining of γH2AX-foci was performed in parallel at several
time-points after treatment with RT [14]. Second, the clinical in vivo results were then compared
(in silico) with a dynamic mathematical model for DNA damage formation and repair. With the
postulation of a second order decay (removal) of DNA fragments in the comet tail, the goal of the
introduction of clinical patient data into such a tumor-patient model is to identify characteristic kinetic
constants and delay times [15].
By integrating the repeated, minimally invasive in vivo measurements of clinical patients treated
with RT into a mathematical model based data analysis, the potential of a computer simulation of
such time-courses was strengthened. This in turn will allow its future use in a more comprehensive
framework for the interpretation of obtained patient data and for guidance of therapy.
2. Results
2.1. Patient, Tumor, and Radiation Dose Characteristics
Serial samples from eight patients were available. Of the eight dogs, four were female (two spayed)
and four were neutered males. The dogs were of various pure (n = 5) and mixed breeds (n = 3) and
a total of five breeds were represented. The ages ranged from 8.17 to 13.67 years with a mean of
11.28 (±1.63) years. The weights ranged from 11.00 to 38.50 kg, with a mean of 23.73 (±8.51) kg.
Tumor volumes ranged from 9.24 to 97.91 cm3 with a mean of 27.43 cm3 (±29.33). Of the eight cases,
six tumors (75%) were histologically described as canine soft tissue sarcoma and two (25%) as oral
malignant melanoma. Radiation therapy was applied in 5 × 6 Gy over 2.5 weeks in seven patients and
in 4 × 8 Gy in one patient (with malignant melanoma).
2.2. Comet Assay: Tail Intensities (%DNA in Tail) after Radiotherapy in Tumor Samples
Compared to pre-treatment (T0), the measured %DNA tail peaked at 15 to 60 min after RT.
The maximum %DNA in tail was observed at 15–60 min after irradiation, with a rapid decrease at
120 min (Figure 1). The median tail intensities differed significantly up to and including the 60 min
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post-treatment time point (p ≤ 0.001). Afterwards, already after 120 and 360 min a rapid decrease was
found. The same low intensities were observed before the second fraction, where median tail intensity
was not significantly different from T0 anymore. (Table 1 and Figure 1).
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T0 → T15 10.80 (6.56; 15.04) p = 0.001 
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T0 → T60 7.11 (4.52; 9.71) p < 0.001 
T0 → T120 2.47 (−1.41; 6.36) p = 0.172 
T0 → T360 1.24 (−0.86; 3.33) p = 0.185 
T0 → Tbefore 2nd fraction 1.56 (−0.87; 3.99) p = 0.168 
2.3. Phosphorylated H2AX (γH2AX): Number of Positive Cells and Foci per Cell after Radiotherapy in  
Tumor Samples 
Samples from three time-points (T0, T30, T360) of the included patients were analyzed for the 
number of positive cells (%), as well as foci/cell (Figure 2). Both the amounts of positive cells as well 
as the numbers of foci per cell at T30 and T360 were significantly different from those at T0 (p < 0.001 
for positive cells; p = 0.002 for foci/cell). As shown in Table 2, both values had returned to baseline 
before the second fraction. The concurrently sampled co-irradiated normal tissue from the tumor 
patients followed the same pattern regarding the disappearance of foci (Figure 3). 
Figure 1. Time-course of DNA damage measured by co et assay. Tail intensity ( DNA in tail)
measured at indicated time-points after completion of radiation treat ent ( 0–before treat ent, T15,
T30, T60, T120, T360, i tes fter treat ent, respectively). Mean values ± SD are shown. Significances
in differe i l i l 1.
Table 1. Differences of median tail intensity (%DNA in tail), comet as ay (%; 95% CI). 0, 15, T30, etc.
indicate the time-points in minutes after completion of radiation treat e t.
Time-Points Difference of %DNA in Tail (95% CI) p-Value
T0 → T15 10.80 (6.56; 15. 4) p = 0.001
T0 → T30 11.24 (6.38; 16.10) p = 0.001
T0 → T60 7.11 (4.52; 9.71) p < 0.001
T0 → T120 2.47 ( 1.41; 6.36) p = 0.172
T0 → T360 1.24 (−0.86; 3.33) p = 0.185
T0 → Tbefore 2nd fraction 1.56 (−0.87; 3.99) p = 0.168
2.3. Phosphorylated H2AX (γH2AX): Number of Positive Cells and Foci per Cell after Radiotherapy in
Tumor Samples
Samples from three time-points (T0, T30, T360) of the included patients were analyzed for the
number of positive cells (%), as well as foci/cell (Figure 2). Both the amounts of p itive cells as well
as the numbers of foci per cell at T30 and T360 were sig ificantly different from those at T0 (p < 0.001 for
positive cells; p = 0.002 for foci/c ll). As shown in Table 2, both values had returned to baseline bef e
the seco d fraction. The concurr ntly sampled co-irr diated normal t ssue f om the tumor patients
followed the same pattern regarding the disappearance of foci (Figure 3).
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Figure 3. Time-course of γH2AX imm istochemic l labeling in norma epithelium, soft tissue
sarcoma, and malignant melano a. All tissues show low γH2AX reactivity before radiotherapy,
high numbers of γH2AX positive cells and foci per cell at 30 min after radiotherapy, and a decrease
of the respective numbers at 360 min after radiotherapy. (RT = radiotherapy; bars: overview 20 µm,
insert 15 µm); (Immunoperoxidase, haematoxylin-conterstain: brown intranuclear dots represent
γH2AX-foci).
Table 2. (a) Positive staining for γH2AX-foci (%). T0, T30, T360, etc. indicate the time-points in minutes
after completion of radiation treatment. (b) Number of γH2AX-foci per positive cell. T0, T30, T360, etc.
indicate the time-points in minutes after completion of radiation treatment.
(a)
Time-Points Median γH2AX Positive Cells (%; 95% CI) p-Value, Compared to T0
T0 20.17 (3.89; 62.36)
T30 87.18 (81.75; 91.78) p < 0.001
T360 78.48 (41.88; 85.67) p < 0.001
Tbefore 2nd fraction 15.61 (9.80; 41.44) p = 0.764
(b)
Time-Points Median γH2AX-Foci Per Nucleus (95% CI) p-Value, Compared to T0
T0 2.13 (2.00; 3.50)
T30 8.00 (6.00; 15.00) p < 0.001
T360 4.00 (3.00; 8.00) p = 0.002
Tbefore 2nd fraction 2.00 (2.00; 2.00) p = 0.163
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2.4. Covariate Analysis
Due to the time dependence, a linear mixed model approach was applied to detect associations
between the median tail intensity, median positive cells, median foci/cell, and covariates such as age,
gender, tumor volume, and cancer type. No influence of the covariates or the different fractions of
serial measurement was detected.
2.5. Baseline Levels of γH2AX in Tumor Biopsy Samples of Various Histologies
Samples of various histologies (soft tissue sarcomas (n = 16), malignant melanomas (n = 19),
carcinomas (n = 25), and malignant lymphomas (n = 23)) were taken from patients undergoing surgical
tumor removal for diagnostic or treatment purposes at the clinic (see Table 3 for patient-specific details).
While the sampling groups did not vary in gender (p = 0.186), age (p = 0.014, malignant lymphoma
younger than malignant melanoma patients) and weight (p = 0.016, soft tissue sarcomas heavier than
malignant melanoma and carcinomas patients) showed some (clinically non-relevant) differences.
Histologically, the malignant lymphoma tumor group had significantly higher values in foci/cell
(p < 0.001) compared to the population with soft tissue sarcoma, malignant melanoma, or carcinomas
(Figure 4). In terms of positive cells (p = 0.014), the malignant lymphoma tumor group had significantly
higher values than the population with soft tissue sarcoma.
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Table 3. Patient specific details for baseline values of γH2AX foci. f = female, fs = female spayed, m = male, mn = male neutered.
Tumor Type Age (Years)Mean (SD; Range)
Weight (kg)
Mean (SD; Range) Gender
Median Positive
Cells (%) 95% CI p-Value Median Foci/Tumor 95% CI p-Value
Overall
(n = 83)
9.89 (±2.92;
1.00–15.00)
23.70 (±10.90;
3.60–55.00)
f = 14
fs = 27
m = 19
mn = 23
20.72 21.88; 24.29 0.014 2.50 2.40; 2.90 <0.001
Soft tissue
sarcoma
(n = 16)
9.74 (±1.80;
5.92–12.83
30.40 (±9.88;
14.20–50.70)
f = 3
fs = 7
m = 3
mn = 3
13.41 7.42; 20.59 2.00 1.50; 2.47
Malignant
melanoma
(n = 19)
11.71 (±2.59;
6.00–15.00)
19.24 (±8.78;
3.60–30.50)
f = 2
fs = 4
m = 7
mn = 6
15.35 12.25; 28.22 2.50 2.14; 2.99
Carcinoma
(n = 25)
9.48 (±3.33;
1.00–15.00)
20.79 (±10.23;
4.50–35.50)
f = 6
fs = 6
m = 8
mn = 5
18.12 14.55; 28.67 2.00 2.03; 2.81
Malignant
lymphoma
(n = 23)
8.94 (±2.67;
3.58–13.75)
25.88 (±11.04;
9.00–55.00)
f = 3
fs = 10
m = 1
mn = 9
31.30 24.72; 34.93 3.00 2.87; 4.04
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2.6. Quantification of the Time-Course of DNA Damage and Repair Using Novel Mathematical Modeling
The evolutionary parameter search (based on the median %DNA in tail) revealed a good fit
to the in vivo data for the pooled sarcoma group time-course when both pathways (fast and slow)
were active. In order to simplify the model, we tested the case where only the fast pathway was
active. This fit had a larger error (Table 4) but in relation to the variability of the data (Figure 5A),
it covered the experimental results reasonably well. Selected fits for time-courses of specific fractions
are shown in Figure 5B–D. This more detailed display shows how pooling individual fractions and
time-courses obtained from different patients can cover up a part of the heterogeneity of the in vivo
data. As a consequence, the errors are generally larger than in pooled datasets. The data of the
melanoma cases was deemed not suitable for similar analyses, as only time-courses of two patients
irradiated at different fractionation schedules were available.
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%DNA in tail of all patients over three fractions for sarcoma cells, with only the fast repair pathway
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Table 4. Parameter sets of the bio-mathematical model for the sarcoma group. For the final repair step,
second order kinetics was assumed and the data is given in %DNA. The numbers in parentheses in
column 1 (sarcoma, pooled) are for a fit of the full model; for the other values in this column, only one
pathway is active. The remaining columns contain the fitted parameters of individual patient fractions.
Parameter Sarcoma, All Patients andFractions Pooled
Patient 1,
Fraction 1
Patient 2,
Fraction 1
Patient 2,
Fraction 2
kcleav/min−1 1.93 (1.96) 1.12 1.71 1.71
k0, f ast/min−1 3.93·10−1 (1.59 × 10−1) 3.76 × 10−2 4.35 × 10−3 5.24 × 10−2
k1, f ast/min−1 2.92·10−2 (3.44 × 10−2) 2.55 × 10−2 5.24 × 10−2 1.39 × 10−1
k2, f ast/min−1 1.00·10−2 (9.01 × 10−3) 8.45 × 10−2 2.65 × 10−2 1.01
k0,slow/min−1 - (3.22 × 10−3) - - -
k1,slow/min−1 - (1.01 × 10−3) - - -
k2,slow/min−1 - (1.23 × 102) - - -
tr,slow/min - (7.07) - - -
tr, f ast/min 1.28·101 (1.09 × 101) 1.93 × 101 8.51 × 10−1 3.77
bn/% DNA 4.23 (4.09) 2.94 7.12 6.35
Error of fit 1.20 (1.03) 7.31 × 10−1 1.23 × 101 6.97 × 101
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3. Discussion
Neither DNA damage induction, nor repair time-courses have been described from patients
undergoing radiation therapy up to the present date. Hence, very little is known about the amount of
actual DNA damage and the kinetics of repair in tumors in vivo, or in normal tissues under antineoplastic
treatment. Herein, we used repeated samples from dogs with primary tumors undergoing therapeutic
radiation therapy. Spontaneous tumors in companion animals like dogs are described to offer a unique
opportunity as a model for human cancer biology and translational clinical research [15,16]. In contrast
to most murine tumor xenograft studies, cancers in dogs arise over the background of an intact
immune system and present many features like histological appearance, tumor genetics, molecular
targets, biological behavior, and response to conventional therapies, as well as inter-patient tumoral
heterogeneity common to humans [15]. Moreover, in many ways, a canine model serves even better
than a murine one to study DNA damage repair (DDR) and its defects in vivo, as in rodents, certain
repair pathways seem to be less active in comparison to the human mechanisms, displaying a potentially
different emphasis and hierarchy of DNA repair pathways [17].
The intrinsic radiosensitivity of the tumor cells is a major determinant of the treatment response
and outcome, and correlates with a patient’s prognosis [18]. As summarized by McKenna et al.,
the comet assay technique has also been used in a wide range of human tumor cell lines as well as
tissue biopsies and has shown predictive information value of the individual’s sensitivity towards
DNA damaging agents [13]. In the herein presented study, the kinetic median tail intensity (%DNA in
tail) showed a fast time-course, with no significant remaining differences in tail intensity after 120 min
post-radiation in either soft tissue sarcoma or malignant melanoma samples. The alkaline comet assay
was chosen because it is capable of detecting and quantifying effects of low, yet clinically relevant
radiation doses of 0–6 Gy. Under alkaline conditions, DNA is denatured and both single strand
breaks as well as double strand breaks are measured in the tail. In samples of human bladder cancer
tissue irradiated ex vivo, evaluation for radiation induced DNA damage levels were measured by this
method and the extent of comet formation was found to correlate with cell killing [6]. Furthermore,
in this bladder cancer patient cohort, reduced DNA damage sensitivity was associated with poorer
treatment outcomes, implying a clinical predictive potential for treatment-induced DNA damage
detection with the alkaline comet assay in certain tumors [6,19,20]. However, the alkaline comet assays
are able to detect both double and single strand breaks [21,22]. Hence, this assay also detects damage
that is not necessarily directly responsible for cell death, as lethality is most frequently observed after
non- or mis-repaired DSB. The neutral comet assay, on the other hand, can be modified to detect double
strand breaks only, but this requires doses of radiation far higher than the clinically relevant ones.
As a general advantage, the comet assay is a relatively inexpensive, simple, and fast technique that
can be carried out on single-cell suspensions, and requires only a small number of cells [13]. This is in
contrast to the more widely used clonogenic cell survival assay, which measures a surviving fraction
of tumor cells after a given clinically relevant dose, but takes a number of weeks to be completed,
for example, to obtain the results of clonogenicity of the tumor cells [23]. Showing a strong correlation
between the methods of clonogenic survival and alkaline comet assay at clinically relevant doses in
tumor cell lines, these measurements of initial as well as residual DNA damage can probably be used
to predict radiation sensitivity in patient derived tumor cells as well [19,20,24].
Prior work—including in vivo mouse assays with various cell lines of head and neck carcinoma,
as well as in ex vivo assays using different tumor types from patients—has documented radio-
responsiveness in sensitive and resistant tumor types to be represented by residual γH2AX-foci [1,2,5].
After antineoplastic treatment, the initiation of DNA repair by the two major responsible pathways
is triggered by the phosphorylation of the histone protein H2AX, which leads to formation of
γH2AX-molecules at the site of the DSB [4,25,26]. Upon repair, the γH2AX-foci will disappear
over a time-course, mostly in concert with DSB rejoining, but it is also suggested that a part of
foci removal depends on subsequent steps of DSB rejoining [25,27]. Several reports describe the
induction and decline of γH2AX foci in vitro [28–31], and also in cancer and normal tissues irradiated
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in/ex vivo [2,5,32,33]. It has been reported that γH2AX foci number in bone marrow cells of mice
irradiated with 4 Gy peaked at 1 h after treatment and decreased to baseline already after 4 h, while,
in contrast, γH2AX foci were still present in irradiated spermatocytes and round spermatid after
48 h [33]. The kinetics of foci induction and disappearance depends on the dose of ionizing radiation,
intrinsic cellular radiosensitivity, cell cycle phase and DNA content, the baseline levels of γH2AX, and,
furthermore, on microenvironmental conditions such as tissue oxygen concentration [34]. In accordance
with our observations, there is a general pattern of acute increase right after irradiation (5–30 min)
with decrease between 0.5 h and 24 h after irradiation, depending on the type of tissue or cells [35].
As a common finding in cultured cancer cells as well as in malignant human tumors of different origins,
untreated canine cancers also contain elevated levels of spontaneous γH2AX-foci, which are thought
to represent inherent genomic instability [30]. The overall median number of 2.5 foci per cell found
herein, ranging from 1.5–2.5 in soft tissue sarcomas to 2.9–4 in malignant lymphoma (e.g., high-grade
non-Hodgkin’s lymphoma) was within the range of 1–20 foci per cell described in human cancers
and various canine cell lines [30,36]. In line with our data, other recent reports show continuous
activation of DNA-repair pathways and constitutive expression of γH2AX in human diffuse large
B-cell lymphoma [28,37].
The bio-mathematical model chosen can be used to describe the comet assay derived data for
sarcoma, even when only one pathway is assumed to be active. The evolutionary parameter search
seems to be very sensitive to the constraints set for the optimization runs. In contrast to other
models [38,39], the model used in this work summarizes the different steps in a repair pathway by
a delayed process. The consequence of this approach is, on one hand, a reduction of parameters
but, on the other hand, a model containing Delay Differential Equations (DDE), which makes the
evolutionary parameter search more difficult. The interpretation of parameter values derived by fitting
the comet data in this work remains challenging at this point, as they vary over several orders of
magnitude. The time delays found range from less than one minute (patient 2, fraction 1) to almost
20 min (patient 1, fraction 1), for example. Yet, based on the plots shown in Figure 5 and the large
variability in the data, the derived values seem plausible. A better aggregation of parameter values may
be reached (1) by modeling distributions instead of relying on median values, and (2) by improving
time resolution, especially at the time-point of 240 min. The comparison with time-resolved γH2AX
foci signals may be another option; however, the decay of γH2AX foci is slower, possibly due to
remaining residues of attached ATM after DNA strands are joined, and therefore could mask the real
dynamics of repair (e.g., the time-course of DSB elimination) [40]. In order to optimally distinguish
between Homologous Recombination (HR)- and Non-Homologues End-Joining (NHEJ)-pathways,
time resolved data from specific markers such as RAD51 for HR, and 53BP1 for NHEJ should be
included in the model. To gain deeper insight into the full dynamics of the involved repair processes,
dose-rate dependent data could also be included, representing a general limitation of using material
from patients with spontaneous tumors. A thorough characterization from in vivo samples is more
difficult compared to well-defined cell lines treated in vitro.
In this study, after a first data screening, we decided to average the data of sarcoma patients
for the initial modeling. One has to keep in mind that differences in intrinsic radiosensitivity in
tumors of the same histological origin exist and can be notable [30,41,42]. It is therefore important
not only to investigate the pooled time-course (Figure 5A), but to also review the data before pooling
(Figure 5B–D). Thereby, a considerable heterogeneity in the time-courses can be revealed, in particular
between fractions of the same patient. While the time-course shown in Figure 5B resembles a scaled
version of the pooled time-course, the one shown in Figure 5C is much slower. Furthermore, the median
%DNA in tail at T30 is higher than the one at T15. Since damage is only induced during irradiation
and is then assumed to decrease, the model cannot produce such a time-course. Instead, parameter
estimates are found that yield a prediction between those two median values. While the variation
in medians between T15 and T30 is well within the range of the error, the discrepancy between the
medians and the model prediction lead to an increased error of fit. Figure 5C shows another fraction
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of the same patient, again presenting a different time-course with a shorter delay and faster decay.
The median at T30 is low compared to the surrounding medians, resulting in an even larger error
of fit. As a limitation of the study, the time-courses from a limited number of patients presented
herein do not allow any conclusions to be drawn on individual radioresponsiveness or prognostic
relevance of these findings. As a further general limitation of this in vivo approach, minimally
invasive and repetitive tumor sampling bears the risk of a mis-representation of the tumor as a whole,
due to intra-tumoral heterogeneity in the extent and distribution of malignancy, stromal reaction,
inflammatory cells, necrosis, and hypoxia. The sampling heterogeneity with fine needle aspirates
and subsequent comet assay might falsely reflect the intrinsic radiosensitivity or repair capacity of
a certain area, and manipulation of single tumor cells and tissues can induce further sampling error.
Sanguineous contamination may occur, leading to measurement errors with very high DNA intensities
in the comet tail, an intensity error that can also be produced by early apoptotic cells [13,43]. Concurrent
microscopic evaluations of FNA samples are recommended to assess the representativeness of a sample.
These limitations, however, reflect the clinical situation in any predictive testing for individual patients
with the goal of personalized medicine and cannot be completely circumvented. However, in patient
sample dependent mathematical data modeling, they can be in part attenuated by choosing a high
time resolution and large individual sample size.
At early time-points after RT, quantification of γH2AX foci was impaired due to foci overlap.
This is a phenomenon that is also problematic for immunofluorescent staining and computerized
quantification. In our evaluation, samples with foci numbers higher than 10 were adjusted as “25 foci”
per cell. This was the case in samples taken 30 min and 6 h after irradiation. Furthermore, there is
an ongoing debate in the literature regarding what should be considered as foci, which is also related
to certain subjectivity in manual scoring [44].
In conclusion, we confirm the clinical feasibility of repeated in vivo minimally invasive sampling
with FNA as well as small biopsies in order to quantify the amounts and time-courses of DNA damage
produced by therapeutic RT. Both dynamics of comet tail intensity and γH2AX-foci could be tracked
during a course of radiation and the resulting data could be integrated into a dynamic mathematical
model for DNA damage formation and repair. By evaluating not only initial or residual DNA damage,
but following a time-course of an individual patient, DNA repair can be quantitatively described.
4. Materials and Methods
The current investigation involved samples of canine tumor patients with various types of
cancers. In repeated samples from patients treated with RT, DNA damage formation and repair
was assessed with comet assay (an assay used to investigate DNA damage in human biomonitoring
and genotoxicology) [11–13] and γH2AX immunohistochemistry (representing an early event after
double-strand break formation) [14,45] at defined time points. The resulting findings were then
integrated into the bio-mathematical repair-pathway model in order to perform a model-based analysis
of comet data. Additionally, biopsies of various tumors were screened with immunohistochemistry
for the amount of pre-treatment γH2AX levels in order to define a baseline of DNA damage in
canine tumors.
4.1. Patients and Sampling Procedures
Dogs presented to the Division of Radiation Oncology, Vetsuisse Faculty, University of Zurich,
Switzerland for treatment of bulky malignant tumors between March 2014 and December 2015 were
included in the study. Each dog had a clinical work up (tumor staging) as appropriate to the type
of presenting disease. Written owner’s consent was obtained for invasive sampling in this study.
This study was carried out in strict accordance with the recommendations and the protocol approved
by the Animal Ethics Council of the Canton of Zurich, Switzerland (Permit Numbers: 180/2011,
7 December 2011) and (ZH108/15, 14 January 2016). All invasive sampling procedures were performed
under anesthesia, and all efforts were made to minimize suffering. In addition, in order to investigate
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the basal level of γH2AX, a series of tumor biopsy samples of various histologies (soft tissue sarcomas,
malignant melanomas, carcinomas, and lymphomas) were taken from patients undergoing surgical
tumor removal for diagnostic or treatment purposes at the clinic.
For comet assay analysis, tumor cells were collected with a minimally invasive method using
fine-needle aspiration (FNA): Sampling was performed with a 5-mL syringe attached to a 22-gauge
needle as previously described [46]. The aspirated volume of 10 µL was immediately mixed with
a freezing solution of 440 µL fetal calf serum (FCS, Gibco, Thermo Fisher Scientific, Reinach, Switzerland)
and 50 µL dimethyl sulfoxide (DMSO, Sigma-Aldrich, Buchs, Switzerland) in pre-cooled cryotubes.
Cryotubes were stored at −80 ◦C until a comet assay was performed. FNA samples from the tumor site
were taken in duplicates 15 min before RT and 15, 30, 60, 120 min, and 6 h after RT during the multiple
fractions of radiotherapy.
Tumor biopsies for γH2AX immunohistochemistry were collected using 12-gauge Bard®
Biopty-Cut® Disposable Core Biopsy Needles, and normal, co-irradiated tissue was sampled with
4 mm punches. Tissue was fixed for 24 h in 10% buffered formalin and embedded into paraffin wax by
routine methods. Samples were taken 15 min before, and 30 min and 6 h after RT treatment.
4.2. Treatment
Radiation was delivered with a 6 megavolt (MV) linear accelerator (Clinac iX, Varian, Palo Alto,
CA, USA) using either photons or electrons, depending on tumor size and location. Treatment
planning was performed on the basis of computer tomography (CT) for photon plans or by hand
calculation for electron plans. During treatment, dogs were under general anesthesia using propofol for
induction of anesthesia and sevoflurane for maintenance of anesthesia, immobilized in an individually
shaped vacuum cushion, and, if required, additionally equipped with a custom-made bite block.
The recommendations for specifying dose and volumes as proposed for veterinary medicine were
adhered to as proposed in the corresponding literature. The prescribed dose was 30 Gy, delivered in
five fractions of 6 Gy applied twice per week, resulting in an overall treatment time of 2.5 weeks [47–49].
4.3. Alkaline Comet Assay
After thawing, the FNA samples were mixed with 9 mL of ice-cold phosphate-buffered saline
(PBS) and centrifuged for 10 min (1500 rpm, 4 ◦C). The pellet was re-suspended in 100 µL of ice-cold
PBS. A volume corresponding to approximately 170,000 cells was mixed with 90 µL of agarose (1% low
melting point agarose (LMPA, Trevigen, Gaithersburg, MA, USA) in PBS, 37 ◦C. Subsequently, 25 µL of
agarose-cell solution was pipetted onto 20-well slides (Trevigen, Gaithersburg, MA, USA) in duplicate.
The loaded slides were then placed at 4 ◦C for 5 min to allow agarose polymerization, and subsequently
placed in lysis buffer for 1 h at 4 ◦C, followed by incubation twice in ice-cold alkaline electrophoresis
solution (pH > 13.0) for 10 min at 4 ◦C in the dark. After electrophoresis (300 mA, 15–20 min), the slides
were incubated twice for 10 min in dH2O at room temperature, followed by incubation in 70% ethanol
for 5 min at room temperature in the dark. After complete drying, 70 µL of diluted SYBR-Green
(1:10,000 in TE, pH 8) was pipetted on every well, and the slides were incubated for 15 min in the dark.
The slides were washed twice for 10 min in dH2O at room temperature. To provide a quantitative
analysis of obtained comets (%DNA in tail, tail intensity), the COMET IV® scoring system was used.
4.4. γH2AX Immunohistochemistry
Information about antibodies, pretreatment, incubation conditions, and visualization are reported
in Table 5. For immunohistochemical staining, a Dako Autostainer (Dako, Baar, Switzerland) was
used. Three-micrometer (3-µm) sections were mounted on positively charged slides (Superfrost Plus,
Thermo Fisher Scientific, Reinach, Switzerland), dried overnight at 37 ◦C, deparaffinized, rehydrated,
and immersed for 10 min in 10% hydrogen peroxide to block endogenous peroxidase activity. Antibody
diluent (S2022) and wash buffer (S3006) from Dako (Baar, Switzerland) were used. Negative controls
were done omitting the primary antibody.
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Table 5. Antibodies and incubation conditions. Primary antibody, treatment, and incubation conditions,
* HIER = heat − induced epitope retrieval, carried out in a steamer (Pascal S2800, Dako).
Antigen Vendor AntibodyType
Catalogue
No./Clone
Dilution,
Incubation
Conditions
Pre-Treatment VisualizationMethod
Positive
Control
γH2AX
Ser 139
Millipore
Temecula,
CA, USA
mouse
mAb, IgG1
05-0636/clone
JBW301
1:200, 1.3 h, room
temperature
HIER *, 20 min
98 ◦C, citrate
buffer pH 6.0
Envision Kit
(Dako)
Irradiated
canine tumor
tissue
The quantification of γH2AX positively stained cells and γH2AX foci was performed by manual
counting by one investigator (NS) after reaching internal consensus on the procedure. The tumor slides
were scanned and analyzed with NanoZoomer 2.0-HT scanscope (Hamamatsu, CH-4500 Solothurn)
and visualized using the NDP.view2 software (Hamamatsu). For each tumor, 10 fields of identical size
(50×magnification) were set randomly, but dispersed over non-necrotic tumor areas. Furthermore,
in each tumor, the number of γH2AX foci were counted in the nuclei of 300 cells.
4.5. Bio-Mathematical Modeling
For the bio-mathematical model, the following initial assumption was made: DNA breaks can be
processed by (1) a fast repair pathway reflecting Non-Homologues End-Joining (NHEJ) for DSB or
SSB-repair by PARP-1/XRCC1/DNA repair module, which may also be involved in the DSB repair
by the B-NHEJ backup pathway [50] or by (2) a slower repair pathway (Homologous Recombination
(HR) for DSB). Due to the lack of pathway-specific markers in this study, we cannot allocate the two
pathways of the model to either HR and/or NHEJ repair mechanisms. We therefore named the two
pathways slow and fast, leaving their connection to HR and NHEJ open. Since SSB is also observable
in an alkaline comet assay, it can be expected that DNA-fragments produced by direct DSB will be
flanked by those initially produced by SSB. The decision to start with the described two pathways
was biologically motivated and based on a preliminary analysis of the comet data from melanoma
(data not shown). We found that the two-pathway model did not bear significant advantages over
a one-pathway model for the sarcoma data. In particular, the two-pathway model failed to reveal two
co-existing repair processes. The parameters resulting from the fitting procedure suggest that one
pathway dominates (see Table 4). The model was thus simplified to a one-pathway model by forcing the
reaction rates of the slow pathway to 0. Due to the symmetry in the model, this is equivalent to setting
the fast pathway to 0. After this simplification, the term fast lost its meaning, as only one pathway
remains in this model. This entails a modest increase in error of fit due to the loss of four parameters.
In Figure 6, a flow chart for the two-pathway model is shown: DNA damages (number n0; including
SSB and DSB) are produced with an induction rate proportional to the dose rate R (dn0/dt = kcleavR;
kcleav is a cleavage constant). Since there is a large number of remaining potential target sites (DNA
fragments in tail typically below 25%), it is assumed that there is no saturation effect. It has to be
pointed out here that this is a simplistic approach for fragment generation. Since a fragment will be cut
out of a DNA strand by two hits, one would expect an additional dependence of the absorbed dose D at
the corresponding time t: dn0/dt = kcleavR·D. In addition, pre-existing, non-radiation induced breaks
can lead to the liberation of a fragment when a second, radiation-induced break will occur. This process
is then, as initially assumed, simply proportional to the dose rate. Both possibilities combined will
yield dn0/dt = kcleavR·(ε+ D) , where ε is a dose-equivalent for pre-existing, not-radiation induced
breaks. Simulations with the different models and varying parameter values for ε resulted only in
different values for kcleav without significant impact on the terminal course of the number of fragments
in the tail. Since the number of data points is limited and experiments were performed at only one
dose rate, we decided to use the simplest approach for fragment generation in this study.
The primary damages (n0) can be detected by one of the two repair pathways and then
transformed to damages prepared for the fast (n1, f ast) or the slow (n1,slow) pathway. For this process,
first order kinetics are assumed with reaction rate constants k0, f ast and k0,slow, respectively. After
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detection by a repair-pathway, the damages are processed and prepared for end-joining, or in the case
of HR, homology search. This process is also assumed to be of first order with reaction rates k1, f ast
and k1,slow, delayed by tr, f ast and tr,slow, respectively. The amount (number) of processed damages
is denoted by n2, f ast and n2,slow, respectively. The damages are finally repaired by a second-order
process. It is further assumed that all types of damages (n0, n1, f ast, n1,slow, n2, f ast, n2,slow) can be
transported by electrophoresis and are therefore visible in the comet tail. The total amount of damage
predicted by the model is the sum of all damages ni along with a baseline value bn that is co-evolved
during optimization. Free DNA fragments fade away by the final repair process step at rates of k2, f ast
and k2,slow, respectively. This process is described by second order kinetics in the model, since two
fragments are joined together. The full set of equations of the mathematical model and parameter
values is given in the supplementary materials.
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Figure 6. Process flow chart for the two-pathway model. Primary damages (n0) are detected by one
of the two repair pathways and then transformed to damages prepared for the fast (n1, f ast) or slow
(n1,slow) pathway (by a first order kinetics). The damages are further processed and prepared for
end-joining, or in the case of HR, homology search. Processed DNA fragments (n2, f ast and n2,slow) fade
away by the final repair step (second order kinetics). The full set of equations of the mathematical
model is given in the supplementary materials.
For the model-based analysis, the median values of %DNA fragments in comet tail have been
calculated. To determine the parameter values in the model, an evolutionary optimization algorithm
using a gradient search method was applied [39].
4.6. Statistical Methods
Data were coded in Excel and analyzed with SPSS version 21. Descriptive statistics such as means,
standard deviations, medians, interquartile ranges (IQRs) together with corresponding 95% confidence
intervals (95% CIs) were computed. The non-parametric Spearman correlations for associations
between two continuous variables were computed. Due to the time dependence, a linear mixed model
approach was applied to detect associations between the comet median tail intensity in % (0, 15, 30, 60,
120, 360 min after RT and compared to the beginning of the next fraction), median γH2AX positive
stained cells in %, median number of γH2AX foci per cell (0, 30, 360 min after RT and compared to the
beginning of the next fraction) adjusted for the following predictors: age, gender, tumor volume, and
histological group.
For the analysis of the baseline levels of γH2AX in tumor biopsy samples of various histologies,
the Kolmogorov-Smirnov test was applied to check the correctness of normality assumption of the
median γH2AX positive stained cells in % and median number of γH2AX foci per cell. The one-way
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ANOVA together with the Scheffé post-hoc test approach was taken to investigate differences in
primary outcomes of median γH2AX positive stained cells in % and median number of γH2AX foci in
the nucleus, age, and weight with respect to diagnostic code. The association between the diagnostic
code and gender was checked with the Chi2-test. Results of statistical analysis with p-value < 5% were
interpreted as statistically significant.
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